Cost-benefit of drug eluting stents - Time for a reality check

Heart Lung and Circulation

Volumn 14, Issue 2, 2005, Pages 74-77

  Ward, Michael R ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Coronary intervention; Cost effectiveness; Drug eluting; Restenosis; Stent

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HOSPITAL; REOPERATION;

EID: 21244473023     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2005.03.005     Document Type: Article

References (13)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
5. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
6. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108:257-60 [Epub 2003 July 14].
7. http://www.jnj.com/news/jnj_news/20020307_1722.htm.
8. www.ptca.org/press_rel/20020924pr_boston.html.
9. NHCDC Round 6 (2001-02). www.health.gov.au/casemixecosting/fc_r6.htm, 2002.
10. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003;107:3003-7.
11. O'Neill WW, Leon MB. Drug-eluting stents: costs versus clinical benefit. Circulation 2003;107:3008-11.
12. Gunn J, Morton AC, Wales C, Newman CMH, Crossman DC, Cumberland DC. Drug eluting stents: maximising benefit and minimising cost. Heart 2003;89:127-31.
13. Hodgson JM, Bottner RK, Klein LW, Walpole Jr HT, Cohen DJ, Cutlip DE, et al. Drug eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care and medicoleglas issues. Cath Cardiovasc Inter 2004;62:1-17.